ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives.
CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences.
'This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility,' said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. 'As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders.'
Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs.
'We are excited to work alongside the team at IPA,' said Scott Gordon, Co-Founder and President of CORE IR. 'IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community.'
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). For more information, visit www.ipatherapeutics.com.
About CORE IR
CORE IR is a strategic communications firm specializing in investor and public relations services. The firm supports public and private companies across a wide range of industries with customized programs to enhance corporate visibility, engage stakeholders, and support business objectives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Drug maker Indivior to abandon London stock market for the US
Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2 billion. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. 'We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The LSE faced the largest exodus of companies since the global financial crisis in 2024, according to EY analysis. There were 88 companies to delist or transfer their primary listing from the main market – the most since 2009. At the same time, the LSE struggled to attract as many new companies to fill the gaps – with 18 new listings in total last year. Nevertheless, Indivior's exit, which will take effect from July 25, comes as Valterra Platinum makes its debut on the London market. Anglo American spun off its platinum business into the new entity, which has become the world's most valuable producer of the metal. Valterra will have its secondary listing on the LSE, with its primary on the Johannesburg Stock Exchange. Duncan Wanblad, Anglo American's chief executive, said: 'Valterra Platinum has been a major part of the company for many years but now is the right time for it to optimise its value creation prospects on an independent path – it's an outstanding business and team and I have every confidence that Valterra Platinum will thrive as a leader in the global platinum group metals industry.' Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Ollie's (OLLI) Reports Q1: Everything You Need To Know Ahead Of Earnings
Discount retail company Ollie's Bargain Outlet (NASDAQ:OLLI) will be announcing earnings results tomorrow before the bell. Here's what you need to know. Ollie's missed analysts' revenue expectations by 1.2% last quarter, reporting revenues of $667.1 million, up 2.8% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' gross margin estimates but full-year EPS guidance missing analysts' expectations. Is Ollie's a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Ollie's revenue to grow 11.3% year on year to $566.2 million, in line with the 10.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.71 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Ollie's has missed Wall Street's revenue estimates four times over the last two years. Looking at Ollie's peers in the discount retailer segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Ross Stores delivered year-on-year revenue growth of 2.6%, beating analysts' expectations by 0.5%, and TJX reported revenues up 5.1%, topping estimates by 0.7%. Ross Stores traded down 9.8% following the results while TJX was also down 4%. Read our full analysis of Ross Stores's results here and TJX's results here. There has been positive sentiment among investors in the discount retailer segment, with share prices up 9.8% on average over the last month. Ollie's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $125.88 (compared to the current share price of $110). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Couchbase (BASE) Q1 Earnings: What To Expect
Database as a service company Couchbase (NASDAQ: BASE) will be reporting results tomorrow after the bell. Here's what to expect. Couchbase beat analysts' revenue expectations by 3.1% last quarter, reporting revenues of $54.92 million, up 9.6% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' billings estimates but full-year guidance of slowing revenue growth. Is Couchbase a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Couchbase's revenue to grow 8.2% year on year to $55.56 million, slowing from the 25.2% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.08 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Couchbase has missed Wall Street's revenue estimates twice over the last two years. Looking at Couchbase's peers in the data storage segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Commvault Systems delivered year-on-year revenue growth of 23.2%, beating analysts' expectations by 4.8%, and Snowflake reported revenues up 25.7%, topping estimates by 3.4%. Commvault Systems's stock price was unchanged after the resultswhile Snowflake was up 13.5%. Read our full analysis of Commvault Systems's results here and Snowflake's results here. There has been positive sentiment among investors in the data storage segment, with share prices up 7.6% on average over the last month. Couchbase's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $20.81 (compared to the current share price of $17.61). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
